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PREDICTORS OF SURVIVAL 
IN MALIGNANT TUMORS OF 
THE STERNUM 
From 1930 to 1994, 54 patients with pr imary malignant umors of the 
sternum were seen. Fifty patients were first seen with a mass, and one half 
of them also had pain in the sternal region. Two patients had no symptoms 
at presentation. Among 39 solid tumors were 26 chondrosarcomas, 10 
osteosarcomas, 1 fibrosarcoma, 1 angiosarcoma, nd 1 malignant fibrous 
histiocytoma. Of these, 25 were low-grade and 14 were high-grade tumors. 
Among 15 small cell tumors were 8 plasmacytomas, 6 malignant lympho- 
mas, and 1 Ewing's sarcoma. Part ial  or subtotal sternectomy was done in 37 
patients and total sternectomy in 3. Of the remaining 14 patients, 3 had 
local excision; 10 had external radiation or chemotherapy without opera- 
tion, or both; and 1 had no treatment. All but one patient reated by wide 
resection (N = 40) had some form of skeletal reconstruction of the chest 
wall defect. Thirty-one (78%) underwent repair  with Marlex mesh, and in 
25 this was combined with methyl methacrylate. The skin edges were closed 
per pr imum in 32 patients; 8 required muscle, omentum, or skin flaps. 
Resection in chondrosarcomas yielded a 5-year survival (Kaplan-Meier) of 
80% (median follow-up, 17 years). The 5-year survival in osteosarcomas was 
14%. Resection was curative in 64% of low-grade sarcomas but in only 7% 
of high-grade sarcomas. In small cell tumors, resection and radiation were 
helpful for local control; all failures were a result of distant metastases. We 
conclude that pr imary sarcomas of the sternum though uncommon are 
potentially curable by wide surgical excision. With rigid prostheses to 
repair  the skeletal defects, the surgical complication rates are |ow. Overall 
survival after complete surgical resection is related to tumor histologic type 
and grade. (J TnORAC CARDIOVASC SURG 1996;111:96-106) 
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p r imary mal ignant umors of the sternum gener- 
ally fall into two categories: solid tumors, which 
include pr imary bony or carti laginous tumors and 
soft tissue sarcomas, and small cell tumors, which 
are usually systemic but may present as a local ized 
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sternal mass. This latter group includes Ewing's 
sarcomas, plasmacytomas, and lymphomas. 
Since our report  2 decades ago, 1 new methods of 
evaluation and surgical t reatment  and advances in
techniques of skeletal and musculocutaneous recon- 
structions have faci l i tated the t reatment  of these 
uncommon tumors. To assess results and identify 
predictors of survival, we reviewed our total experi- 
ence with these tumors. 
Pat ients  and methods 
From 1930 to 1994, 54 patients with primary malignant 
tumors of the sternum were seen and treated at Memorial 
Sloan-Kettering Cancer Center. The clinical, surgical, and 
pathologic reports of all patients were carefully reviewed 
to ensure that the tumors were malignant and originated 
from the sternum and no other site. Each tumor was 
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Table I. Histologic type of primary sternal tumors 
1930 to 1994 
Table II. Pretreatment imaging studies in 54 
patients* 
Type No. Study No. 
39 
15 
Solid tumors 
Chondrosarcoma 26 
Osteosarcoma 10 
Angiosarcoma 1 
Fibrosarcoma 1 
MFH 1 
Small cell tumors 
Plasmacytoma 8 
Malignant lymphoma 6 
Ewing's sarcoma 1 
MFH, Malignant fibrous histiocytoma. 
evaluated for size, histologic type, grade, and location. 
The treatments rendered were also recorded. In those 
patients in whom resection was the primary therapy, the 
mode and extent of resection, the size of the skeletal 
defect, and the type of skeletal and cutaneous reconstruc- 
tions were note& Follow-up status and recurrent sites if 
any were also recorded. Survival was calculated by the 
Kaplan-Meier method, 2 and postoperative d aths and all 
cancer-related deaths were included. Differences in sur- 
vival were determined by the log-rank test 3 and differ- 
ences in frequency data by the )(2 test. Significance was 
defined asip -< 0.05. 
Of 39 ~olid tumors, most wem chondrosarcomas or
osteosarcomas (Table I). The 15 small cell tumors were 
mainly plasmacytomas nd malignant lymphomas. 
There Was a near equal sex distribution for all tumors 
seen except for chondrosarcomas for which the male-to- 
female ratio was 2 to 1. The age range was 19 to 78 years, 
with a median age of 54 years. The median age was 55 
years in patients with chondrosarcoma, 40 years for osteo- 
sarcoma, 59 years for plasmacytoma, nd 48 years for 
malignant lymphoma. 
Fifty patients were first seen with a palpable mass, and 
one half of them also had pain in the sternal region. Two 
patients had no symptoms or signs at presentation and the 
disease wa~ detected on lateral chest radiographs. 
The size of the tumor ranged from 3 to 24 cm in 
maximum diameter with a median of 7 cm. All patients 
had imaging studies of the sternum. A few of the earlier 
patients had only radiographs of the chest taken in the 
posteroan{erior and lateral positions with views of the 
sternum in the oblique and cross table lateral positions 
(Table II).; Since then, progressively more refined imaging 
techniqueS ineluded planar tomograms, skeletal surveys, 
bone scans, selective angiograms, and, more recently, 
computed tomographic (CT) scans and magnetic reso- 
nance ima in~ (MRI). 
Radiog~gaphic featüres were speeific only in cartilagi- 
nous tumors. All patients with chondrosarcoma had 
coarse, mdttled calcification within the tumor. Differenti- 
ation betw~en benign and malignant cartilaginous tumors 
was not p0ssible by radiographic criteria, unless cortical 
destruction and involvement of soft tissues were visuM- 
ized. The remaining tumors of the sternum showed no 
constant or d~agnostic features. Most tumors were avas- 
Plain chest radiography 54 
Planar tomography 10 
CT scanning 28 
Bone scan 18 
Skeletal survey 10 
MRI 7 
*Most patients had two or more studies. 
cular. CT and MRI scans were most helpful in defining 
tumor extent (Fig. 1). Radiographically, portions of the 
sternum were free of tumor in alt but five patients. The 
extent of tumor involvement is shown in Fig. 2. 
Tissue diagnosis was established by fine-needle aspira- 
tion biopsy in 3 patients, open biopsy in 38, and at the time 
of definitive operation in 13. Of 39 solid tumors, 25 were 
low-grade sarcomas and 14 were high-grade tumors. Of 
the 26 chondrosarcomas, 9 were grade I, 15 grade IIi and 
2 grade III. The one patient with angiosarcoma had a 
low-grade tumor; all others were high grade. 
Seven of 10 patients with osteosarcomas of the sternum 
had prior external irradiation for Hodgkin's disease in 4 
patients, breast carcinoma in 1, thymoma in 1, and rhab- 
domyosarcoma in 1. 
All patients with small cell tumors underwent bone 
scans to rule out multiple sites. 
Of 39 patients with solid tumors, 1 received no treat- 
ment, 1 received radiation therapy, 2 had local excisions, 
and 35 had wide resections (Table III). Among 15 patients 
with small cell tumors, primary treatment consisted of 
wide resections in 5, external radiation therapy in 7, 
chemotherapy in 2, and radiation plus chemotherapy in 1. 
The extent of resection paralleled the extent of sternal 
involvement. Partial or subtotal sternectomy was done in 
37 patients and total sternectomy in 3. All but 1 patient 
treated by wide resection (AT = 40) required some form of 
skeletal reconstruction f the chest wall. Thirty-one (78%) 
underwent repair with Marlex mesh (Bard Implants, 
Billerica, Mass.), and in 25 this was combined with methyl 
methacrylate (Table IV). The soft tissue and skin edges 
were closed per primum in 32 patients (Table V). Unless 
the entire sternum was involved by tumor, an effort was 
made to conserve part of it, usually the proximal rim of 
the manubrium, and to maintain the circumferential con- 
tinuity of the thoracic cage. By this method, combined 
with adequate skeletal reconstruction, paradoxic motion 
was avoided. The size of skeletal defects in our series 
ranged from 36 cm 2 (6 × 6 cm) to 324 cm 2 (18 × 18 cm) 
with a median skeletal defect of 120 cm 2 (10 × 12 cm). 
There were two postoperative d aths both as a result of 
respiratory failure (1 because of inadequate stabilization 
after total sternectomy and 1 because of pneumonia). 
There were four nonlethal complications: pneumonia (1), 
infection necessitating removal of the prosthesis (2), and 
bleeding (1). Since the advent of rigid prostheses, respi- 
ratory assistance has not been necessary after operation. 
Before the use of Marlex mesh by us in 1971, two patients 
had an elective tracheostomy. Additionally there were 
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Fig. 1. Chondrosarcoma of sternum in 48-year-old female patient. A, Axial CT scan shows 7 cm lobular 
tumor replacing sternum, extending externally to subcutaneous soft tissue and deep to pericardial surface. 
It cannot be determined with certainty whether pericardium is involved. R, right. B, Axial Tl-weighted 
MRI scan with cardiac gating. Deep extent of tumor is well demonstrated. Pericardium isnot seen on scan, 
which suggests adherence to or invasion of pericardium. C, Sagittal Tl-weighted cardiac gated MRI scan. 
Superficial and deep extents of tumor are well demon'strated. Again pericardium is indistinct, suggesting 
involvement by tumor. Patient underwent total sternectomy and remains without evidence of recurrence. 
delayed infections in two patients who had a skeletal 
repair with methyl methacrylate at 9 and 10 years, respec- 
tively, as a result of injury necessitating removal of the 
prostheses. This was preceded in one patient by an 
episode of acute arrhythmia that had necessitated xternal 
cardiac massage, which may have caused injury to the 
sternum. The second patient, an avid tennis player, was 
found at 9 years after operation to have an unexplained 
fracture in the upper portion of the methyl methacrylate 
prosthesis near its attachment to the manubrium. This is 
presumed also to have been a sternal injury from his 
sports activities. It is likely that in both instances there was 
a hematoma in the parasternal rea that became second- 
arily infected with persistent purulent sinus drainage, 
which necessitated removal of the prostheses. 
Surgical technique. The technical pproach in skele- 
tal reconstruetion of chest wall defects with Marlex 
mesh and methyl methäcrylate has been previously 
described by us. 4 For sternal tumors, wide resection 
includes reseetion of the affeeted part of the sternum 
and approximately 2 to 3 cm of costochondral cartilages 
bilaterally (Fig. 3). Usually both internal thoraeie ves- 
sels are sacrificed. The surgical proeedure begins with a 
vertical elliptical ineision from the sternal noteh to 3 to 
4 cm below the tip of the xiphoid process. The ellipse 
taust encompass the prior biopsy site of skin and soft 
tissues. In general the skin and overlying söft tissues in 
primary sternal tumors are not involved and are under- 
mined laterally for 5 to ó cm from each of the lateral 
borders of the sternum. Exeept when the xiphoid is to 
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Fig. 2. Extent of sternal involvement in 54 patients. 
Table I I I .  Treatment 
Solid Small cell 
Primary treatment tumors tumors Total 
Wide resection 35 5 40 
Resection only 29 2 31 
With chemotherapy 6 1 7 
With radiation 1 1 
With radiation and 1 1 
chemotherapy 
Local excision with radiation 2 1 3 
Radiation only 1 6 7 
Chemotherapy only 2 2 
Radiation afld chemotherapy 1 1 
No treatment 1 1 
Total 39 15 54 
be spared, the subxiphoid space is entered, allowing 
digital palpation of the retrosternal space. Mobilization 
is then begun first on one side of the sternum, with 
exposure and division of the ribs at the costochondral 
cartilages. Dissection and mobilization are advanced 
cephalad to the junction of the body and the manu- 
brium or extend into the manubrium itself, sparing the 
uppermost 1 cm of the manubrium in most instances. 
When simflar dissection is done on both sides of the 
midline, a Gigli saw is used to transect the stemum in its 
upper free margin. Both internal thoracic vessels by this time 
would have 'been identified, dissected out, and doubly ligated 
before division. The number of ribs generally resected varies 
from two to eight. 
Chest wall stabilization is achieved in all patients with 
Marlex mesh with or without methyl methacrylate. Su-
tures are placed either through drill holes in adjoining ribs 
or through pericostal soft tissues. 
After skeletal reconstruction, the skin, subcutaneous 
tissues, and underlying muscles are mobilized and then 
approximated generally in the midline in two layers. 
Although the incision is orten placed in the midline over 
the Marlex mesh, healing is per primum and the risk of 
Table IV. Types of  skeletal reconstruction after wide 
resection 
Type No. 
Marlex mesh plus methyl methacrylzte 25 
Marlex mesh 6 
Ox fascia 3 
Fzscia latz 2 
Rib struts and fascia latz 1 
Tantalum mesh 1 
Pectoral muscle flap 1 
None 1 
Total 40 
infection is small if the overlying tissues are adequately 
vascularized. Cosmetic and functional results are satisfac- 
tory and the procedure is generally safe. 
Results 
Results of treatment in solid tumors. Overall 
survival in patients with solid tumors was 49% at 5 
years with a median survival of 33 months (Fig. 4). 
Survival in solid tumors of the sternum was influenced 
by the grade of the tumor. Among 25 patients with 
low-grade sarcomas, 24 of which wem chondrosareo- 
mas, the 5-year survival was 73% as opposed to 7% in 
14 patients with high-grade tumors, 10 of whieh wem 
osteosarcomas (Fig. 5). Reseetion was curative in 16 
patients with low-grade sarcomas, but was curative in 
only 1 patient with a high-grade tumor. 
Overall survival in patients with chondrosarcoma 
was 66% at 5 years and 56% at 10 years with a 
median survival of 17 years. Only 1 patient with 
osteosarcoma was alive and free of disease at 5 years 
(median survival, 12 months). 
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Table V. Types of sofi-tissue/cutaneous 
reconstruction 
Type No. 
32 Primary closure 
With undermining skin edges only 
With relaxing midaxillary incisions 
Pectoral muscle rotation flap* 
Omental flap with split thickness kin graft* 
Myocutaneous flap? 
Delayed pedicle flap 
Total 
30 
2 
3 
2 
2 
1 
4O 
*Repair dictated by two prior local excisions in one patient and preoper- 
ative radiation in one patient. 
l"Both patients had osteosarcoma after radiation. 
Fig. 3. Radiograph of resected chest wall in 54-year-old 
man with low-grade chondrosarcoma of body of sternum. 
Resection included body, xiphoid process, and lower 
portion of manubrium. Tumor is clearly seen in upper part 
of body of sternum. 
Twenty-two patients with chondrosarcoma of the 
sternum were treated by complete resection, 20 by 
partial or subtotal sternectomy, and 2 by total 
sternectomy. Fifteen had no recurrence, 5 had pul- 
monary metastases, and 2 had local recurrence in 
the lower sternal region despite a presumed com- 
plete resection. In both instances, the manubrium 
was uninvolved and spared. Of note is that five 
patients treated by wide resection had prior local 
excisions and external radiation therapy with recur- 
rence at presentation to our center. Three of these 
had no further ecurrence, and two had local recur- 
rences. Both of these patients were treated before 
the advent of synthetic prostheses and their skeletal 
defects were repaired with fascia lata. One patient 
with high-grade chondrosarcoma died of extensive 
pulmonary metastases despite acomplete resection. 
All four patients not treated by wide excision died of 
local recurrence. 
All 10 patients with high-grade osteosarcomas of 
the sternum had subtotal resections of the sternum. 
Three of the resections had positive margins and 
were considered incomplete; local recurrence and 
subsequent pulmonary metastases developed in the 
patients. Seven patients were considered to have 
had a complete resection of all tumor. One died 
after operation of pneumonia and no residual tumor 
was found at autopsy. Five had disseminated metas- 
tases, and one remains alive and free of disease. 
Survival after complete resection in patients with 
chondrosarcoma of the sternum (n = 22) was 80% 
at 5 years (median, 17 years). One of seven patients 
with completely resected osteosarcoma of the ster- 
num survived 5 years (median, 16 months) and is 
alive and well at 11 years (Fig. 6). 
The one patient with low-grade angiosarcoma of 
the sternum remains alive and well 7 years after 
resection. However, the two patients with fibrosar- 
coma and malignant fibrous histiocytoma, respec- 
tively, died of the disease within ó months. 
Results of treatment in small eell tumors. 
Among eight patients with plasmacytomas of the 
sternum, five had no operation, one had local curet- 
ring plus radiation therapy, and two had wide resec- 
tions of the sternum. In four of these eight patients 
multiple myeloma subsequently developed and the 
patients died of the disease. Of the four patients 
who have remained free of disease, one was treated 
by local curetting and radiation (alive at 29 months), 
one by wide resection (alive at 12 months), one is 
alive free of disease at 8 years after chemotherapy 
only, and the fourth, treated by radiation only, died 
of an unrelated cause 14 years after treatment. 
All six malignant lymphomas of the sternum were 
high-grade tumors; four patients had no operation 
and two had sternectomies. Three of those treated 
nonsurgically received external radiation therapy 
and one had chemotherapy. One patient treated by 
radiation for stage I lymphoma remains alive and 
weil at 11 years. A second patient reated by radia- 
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Fig. 5. Survival by grade in patients with solid tumors (N = 39). 
tion had repeated local recurrences treated with more 
radiation and remains free of disease at 16 years. The 
third patient died of local recurrence and distant 
metastases at5 months. The one patient reated with 
chemotherapy only is alive and well at 1 year, but this 
follow-up is too short to be conclusive. One of the two 
patients treated by wide resection was initially thought 
to have a chondrosarcoma onthe basis of open biopsy 
results before operation but the diagnosis of lym- 
phoma was established on paratFln studies of the 
resected specimen. He remains free of disease 11 years 
after trea~ment. The second patient had received 
preoperative radiation and chemotherapy before re- 
section for persistent disease and was lost to follow-up 
at 9 months after operation. 
Overall survival in patients with plasmacytoma 
was 69% at 10 years with a median survival of 132 
months; survival in patients with lymphoma of the 
sternum was 83% at 10 years with a median survival 
not yet reached (Fig. 7). 
The one patient with Ewing's sarcoma was a 
19-year-old girl who died of massive local recur- 
rence within 4 months despite intensive chemother- 
apy and complete resection. 
Discussion 
Primary tumors of the sternum represent about 1% 
of primary bone tumors and fall into two categories: 
solid tumors, the treatment of which is surgical, and 
small cell tumors, for which treatment is primarily 
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Fig. 7. Survival by histologic type in patients with small cell tumors. 
medical with operation offered selectively for local 
control.l' 5
Careful radiologic investigation is necessary to 
assess the extent of the tumor. The mass evident on 
examination is often part of a much larger tumor 
invading the sternum. Planar tomography and skel- 
etal surveys, previously considered part of the stan- 
dard evaluation, have been replaced by CT scans to 
evaluate the extent of the tumor and search for 
pulmonary metastases. 6 High-resolution scans may 
help assess the extent of the primary tumor, partic- 
ularly with respect to mediastinal invasion. MRI 
scans may be useful for large tumors in which 
mediastinal invasion of the pericardium, heart, or 
great vessels may be present. MRI sagittal views may 
be a useful addition to conventional xial scanning. 
Nuclear bone scanning serves to identify osseous 
metastases atother sites. Pulmonary function testing 
is important in patients with chronic obstructive 
pulmonary disease, in the elderly, and in those with 
large tumors necessitating a wide resection. 
In early series most authors recommended resec- 
tion for both diagnosis and treatment. However, an 
effort to establish a preoperative diagnosis is advis- 
able to identify those patients whose primary treat- 
ment consists of chemotherapy or radiation, or both, 
and to distinguish primary from metastatic tumors 
and inflammatory conditions. 
It is recommended that all tumors of the sternum 
be regarded as malignant until proved otherwise. 
Most patients in our series had an incisional biopsy 
done for diagnosis. Aspiration biopsy was not rou- 
tinely recommended because of the low accurate 
diagnostic yield. However, core needle biopsy may 
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be of value, though it was not used in our series. It 
is important to emphasize that the biopsy site should 
be planned in such a manner as to permit its excision 
with the primary tumor if resection becomes the 
treatment of choice. 
Open biopsy may not distinguish between benign 
and malignant cartilaginous tumors. Consequently, 
wide resection becomes necessary in questionable 
cases. Primary resection without biopsy may be 
justified for small lesions less than 3 to 4 cm in 
diameter or when a cartilaginous tumor is suspected 
on a CT or MRI scanning. 
Chondrosarcoma is the most common primary 
malignant tumor of the sternum. 7 Its management 
previously consisted of biopsy, curettage, and radio- 
therapy with little chance of long-term survival 
before wide resection became the treatment of 
choice. 
The aim of operation in solid tumors of the 
sternum is to remove all tumor with clear mar- 
gins. s-13 However, this does not necessarily mean 
total sternectomy. Unless the entire sternum is 
involved by tumor, an effort is made to conserve part 
of it with its attachments o the remaining rib cage. 
Paradoxic motion can be avoided if the circumfer- 
ential continuity of the thoracic age is maintained 
and adequate skeletal reconstruction is done. If the 
tumor is located in the lower sternum, all or part of 
the manubrium can usually be spared. However, 
tumors that involve the upper sternum generally 
necessitate resection of the manubrium and the 
body of the sternum, as well as the adjacent costal 
cartilages. To provide stability to the chest and avoid 
flail, skeletal defects are reconstructed with Marlex 
mesh and:methyl methacrylate. 14-17 Cutaneous re- 
construction is rarely a problem in primary sternal 
tumors despite extensive resection of the sternum. 
The placement of skin sutures in the midline over 
the Marlex mesh does not deter primary healing. 
With the use of rigid prostheses, pulmonary func- 
tion is preserved, early extubation is possible in nearly 
all patientS, and hospitalization becomes horter be- 
cause of fewer complications. In a review from M. D. 
Anderson Cancer Center, is it was noted that ventila- 
tor use was fivefold more frequent in patients who had 
no Marlex mesh reconstruction and that the hospital 
stay was also prolonged. The chest wall is generally 
well-healed and stable in 4 to 6 weeks. 
The grade of the tumor appears to dictate cur- 
ability. Ch0ndrosarcomas u ually are low-grade tu- 
mors and ipatients with these do well. The high- 
grade variants are uncommon but appear not to be 
eradicated by resection. Osteosarcomas of the ster- 
num are usually high-grade tumors and many are 
radiation induced. Again, a total sternectomy is not 
essential. However, adjuvant systemic treatment is
necessary. For the less frequent sarcomas, the extent 
of resection and survival are guided by tumor grade. 
When the skin and soft tissues of the chest wall 
are also involved by tumor or their vascularity 
compromised by prior radiation therapy, extensive 
soft-tissue coverage may be necessary and should be 
properly planned in advance with a plastic surgeon. 
Omentum may be interposed between the Marlex 
mesh and the skin to improve vascularity. Pedicle 
skin flaps and rotation flaps used in earlier years are 
now replaced by myocutaneous and free flaps. An 
overall wound infection rate of 5% is reported in the 
literature,14, 15, 19 and this is consistent with our 
experience. The risks of infection are small if the 
overlying tissues are adequately vascularized. When 
the skin and soft tissues are sacrificed, the infection 
rate may be as high as 20%, because of tissue 
necrosis necessitating removal of the synthetic pros- 
theses. 
Two synthetic prostheses are currently in popular 
use,t5,20, 21 Marlex mesh, which we have used in 
most of our patients, and polytetrafluoroethy!ene* 
prostheses. Either are adequate and the reported 
differences in their benefits are marginal. Providing 
adequate and immediate reconstruction is impor- 
tant. Major sternal resections can be done safely and 
can be curative. Full-thickness resections are more 
complex, require advanced planning, and have 
higher complication rates, mainly because of tissue 
necrosis and secondary infection. 
The use of Marlex mesh to cover chest wall 
defects was described in 1960 by Graham and asso- 
ciates. 22 In 1981, McCormack and associates 4 re- 
ported on 155 patients with chest wall resection. Of 
these 94 underwent repair with Marlex and 12 with 
methyl methacrylate. The overall prevalence of 
wound infection at the time was 5%. 
When repeated resections are done because of 
recurrence after limited excisions, sufficient scarring 
of the mediastinum ay obviate the need for skel- 
etal reconstruction even after a total sternectomy. 
Otherwise, total sternectomy necessitates rigid pros- 
thetic reconstruction. Paradoxic motion of the chest 
may be so severe as to require permanent or pro- 
longed artificial ventilatory assistance. In our early 
*Gore-Tex prostheses: Gore-Tex is a registered trademark of 
W. L Gore & Associates, Inc., Newark, Del. 
1 0 4 Martini et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
January 1996 
experience, this occurred in one patient who re- 
quired ventilator support for 6 months and eventu- 
ally died of respiratory failure. Unfortunately, de- 
spite the introduction of methyl methacrylate in 
skeletal reconstruction f the chest wall and sternum 
more than 20 years ago, there are still occasional 
cases that are treated currently with myocutaneous 
flaps and soft-tissue reconstruction without the use 
of a rigid prosthesis. 
The predictors of survival in 126 patients with 
primary bony and cartilaginous arcomas of the 
chest wall were reported earlier by us 5 and included 
the grade of the tumor, the presence of pulmonary 
metastases at presentation, inadequate or no resec- 
tion, and local recurrence. The same predictors held 
true for the subgroup of tumors originating in the 
sternum. In chondrosarcomas, the single most im- 
portant factor that predicts good outcome is the 
ability to perform a complete resection of the tumor 
at the first operation to prevent local recurrence and 
subsequent metastases. This is not necessarily true 
for cases of osteosarcoma in which survival is poor 
despite resection and adjuvant chemotherapy be- 
comes necessary. Radiation therapy is generally not 
applicable because most (7 of 10 in our series) are 
postradiation sarcomas. 
Although resection has selectively benefited pa- 
tients with plasmacytoma or malignant lymphoma, 
treatment is generally as effective with external 
radiation therapy or chemotherapy. The overriding 
factor that predicts urvival in plasmacytoma is the 
subsequent development of multiple myeloma. 23 In 
this series, multiple myeloma developed in 50% of 
the patients, and these died of the disease. Because 
of this, it is suggested that chemotherapy bea part of 
the primary treatment in these patients. 
In primary lymphomas of the sternum, treatment 
consists of chemotherapy and irradiation. Operation 
is confined to cases in which the diagnosis is in doubt 
or done for salvage after local recurrence or persis- 
tent local disease. 
Only one patient was seen with Ewing's sarcoma 
confined to the sternum. Diagnosis was made by an 
incisional biopsy and despite a complete resection 
and chemotherapy, extensive local recurrence oc- 
curred within 2 to 3 months. The primarY treatment 
for Ewing's sarcoma of other sites is currently 
chemotherapy followed by resection, and this is 
probably applicable to patients who are seen with 
sternal involvement. 
In summary, we conclude that prognosis and 
survival in primary malignant tumors of the sternum 
are tumor dependent. Most solid tumors, notably 
chondrosarcomas, are potentially curable by wide 
surgical excision. With the use of rigid prostheses to 
repair the skeletal defect, the surgical complication 
rates are low. The two main prognostic factors are 
the grade of the tumor and the completeness of the 
resection. High-grade tumors and incomplete resec- 
tions are adverse factors for long-term survival. 
Local recurrence and pulmonary metastases are the 
most common reasons for failure of treatment. 
Treatment of plasmacytoma and primary lympho- 
mas of the sternum is nonsurgical, except when the 
diagnosis is in doubt or as a salvage operation if the 
tumor is still localized after radiation therapy and 
chemotherapy. Hence, it is important o identify 
these tumors before treatment is rendered. 
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Discussion 
Dr. Geoffrey M. Graeber (Morgantown, W. Va.). As this 
presentatioß has pointed out, primary malignant umors 
of the sternum are quite rare. In this paper, the authors 
state that only 54 patients were seen during a 64-year 
period at their facility. In a series that I presented 
previously documenting the experience at the military 
medical centers associated with the Uniformed Services 
University, 110 patients had ehest wall neoplasms during a 
31-year period (Arm Thorac Surg 1982;34:664-73). Only 
two patients, both of them with ehondrosareomas, were 
seen with primary sternal malignancies in that series. 
Benign neoplasms of the sternum do occur, but are 
extremely rare. Metastases to the sternum also oceur, but 
generally are part of a disseminated malignancy. Initial 
presentation of a metastasis as a mass in the sternum 
without radiographic or clinical evidence of other malig- 
nant disease does occur, but is exceptionally unusual. In 
my own personal experienee, I have seen but one patient 
with this unusual presentation. 
The current authors have carefully documented that 
accurate diagnosis of chest wall malignancies, and partic- 
ularly of sternal malignancies, is difficult by either needle 
aspiration or by frozen section. Incisional biopsy may be 
undertaken, but may yield spurious results, particularly in 
chondromatous neoplasms. Unfortunately, incisional bi- 
opsies may sample some of the least malignant areas of a 
chondromatous malignancy. The true malignant potential 
of any such neoplasm can only be ascertained after 
thorough examination of the entire mass by a pathologist. 
The authors are quite right that the outcome of treat- 
ment of any chest wall malignancy is directly related to the 
grade of the tumor and to the completeness of the initial 
resection, when resection is the most appropriate method 
of treatment. The survival reported here of 80% at 5 years 
in malignant chondromatous neoplasms i comparable to 
the 89% we reported when we summarized the military 
experience approximately a decade ago. The experience 
of the Memorial Sloan-Kettering group with osteosarco- 
mas should be viewed with the perspective that 7 of the 10 
osteosarcomas of the sternum they reported arose in 
previously radiated fields. Malignancies caused by radia- 
tion, and particularly sarcomas induced by radiation ther- 
apy, are vicious tumors with unusually malignant poten- 
tial. Most of these tumors prove refractory to virtually any 
therapeutic measures used. 
The work of this group highlights the dilemma of 
proper treatment for small cell tumors of the chest wall. 
Solitary plasmacytomas of the chest wall may well be the 
first presentation of multiple myeloma in a patient. The 
treatment of such patients taust be individualized with the 
knowledge that in the majority multiple myeloma will 
develop. Therapeutic options available for treating achest 
wall plasmacytoma taust be selected carefully. If radiation 
is selected to treat the plasmacytoma, then the dosage 
used must be sufficient o eradicate the neoplasm com- 
pletely because apatient who has received a full course of 
radiation therapy to a tumor without complete resolution 
presents a therapeutic challenge. Such patients usually are 
seen with an open, infected ulcer that has tumor at its 
base. Resection and reconstruction of such a lesion is 
difficult and dangerous because infection and complica- 
tions are much more common. 
The experience of Dr. Martini and his colleagues with 
reconstruction of the chest wall after resection is com- 
mendable. They have clearly demonstrated that stabiliza- 
tion of the chest wall obviates the need for long-term 
ventilation in virtually all cases. Morbidity and mortality 
rates associated with major chest wall resection and 
reconstruction are low, as they have documented. If a 
prosthesis becomes infected, either in the immediate or 
late postoperative period, removal of the prosthetic ma- 
terial associated with proper drainage of the remaining 
pouch yields excellent resolution of the problem. The 
fibrous tissues that have been deposited in reaction to the 
prosthesis and the infection usually ield sufficient stability 
to the chest wall so that respiratory dynamics are not 
compromised significantly. 
I have three questions for Dr. Martini. First, would he 
please document he Memorial Sloan-Kettering experi- 
ence with benign neoplasms of the sternum and tell us the 
most common type of benign neoplasm they have encoun- 
tered? Second, what is his experience and that of his 
colleagues with sternal metastases? Third, what is his 
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opinion of the malignant behavior of radiation-induced 
malignancies, and particularly of sarcomas, of the chest 
wall? 
Dr. Martini. In answer to the first question, the benign 
primary tumors of the sternum are eren rarer than the 
malignant tumors. In a report by us more than 20 years 
ago we had ~dentified only four benign tumors of the 
sternum, three of which were chondromas and one was a 
giant cell tumor. Since then, we have added perhaps two 
more. They are very rare. On the other hand, because 
these tumors are mostly chondromas, tissue diagnosis 
between chondromas and chondrosarcomas may be ditfi- 
cult and a wide resection may be necessary for definitive 
diagnosis. Of greater concern is that chondromas are 
reportedly a group of tumors that can undergo malignant 
degeneration. 
To answer the second question, the focus of our paper 
was on primary tumors of the sternum. Metastases to the 
sternum d0 occur also, but just as uncommonly. The most 
frequent ones we see are metastases as a result of 
recurrence of breast cancer into the chest wall with 
invasion of the sternum and, rarely, solitary metastases 
from kidney or thyroid. The numbers of the latter are very 
small. 
The last question concerned radiatiominduced sarco- 
mas. Our experience has been only with osteosarcomas, 
and, as you weu know, osteosarcomas result in poor 
outcomes at any site in the chest wall, be it scapula, rib, or 
sternum, regardless of complete resection, and this is 
where combined-modality therapy has a role. 
Dr. Peter C. Pairolero (Rochester, Minn.). Dr. Martini 
and associates have a large experience with an uncommon 
problem. Because two thirds of all sternal tumors are 
metastatic, the remaining primary tumors are then ex- 
ceedingly rare, and almost all of these are bone tumors. 
The rarity is again emphasized when one recognizes that 
bone tumors virtually never involve the manubrium or 
sternum. From 1905 to 1993, 11,087 primary bone tumors 
were seen at the Mayo Clinic; however, only 70, or 0.6%, 
were sternal tumors, which is essentially the same preva- 
lence that Dr. Martini has just reported. Of these 70 
tumors, 67 were malignant, and, as with Memorial's 
experience, chondrosarcoma was the most common tu- 
mor. 
As we have heard, chondrosarcomas can be cured by 
aggressive oPeration. Wide radical excision, which does 
not necessarily have to involve the entire borte involved 
but must have a wide margin, preferably 4 cm, is the 
procedure Of choice. Osteosarcoma, however, is much 
more aggressive, with virtually no 5-year survival, as 
evidenced by only a 14% survival hefe in the current 
study. This poor overall survival for osteosarcoma r ises 
the question of neoadjuvant therapy, especially preoper- 
ative radiation, and in our experience, survival appears to 
be greater with this modality. I would like to know 
whether the authors, too, believe that these patients are 
better served with preoperative radiation therapy, and, for 
the same reason, should patients with osteogenic sarcoma 
receive postoperative therapy? 
Aggressive wide radical resection must be balanced 
against durable reconstruction, and this can be achieved 
by a number of methods. In the authors' experience, 95% 
of the patients had skeletal reconstruction. We, too, favor 
this approach, but not for physiologic reasons, inasmuch 
as large portions of the anterior chest wall can be repaired 
with only soft tissue reconstruction and without any 
compromise of pulmonary function. Instead, we favor a 
skeletal reconstruction for protective and cosmetic rea- 
son. 
My last question concerns postoperative management 
and follow-up. What are the authors' recommendations? 
For example, how frequently should a CT scan of the 
chest be obtained? 
Dr. Martini. In osteosarcomas, our experience has been 
with neoadjuvant chemotherapy rather than radiation, 
and in all instances the patients also received adjuvant 
chemotherapy. In this handful of patients who had osteo- 
sarcoma, this combination therapy did not seem to trans- 
late into long-term survival as you noted. Whether the 
radiation therapy appended in the neoadjuvant fashion 
would result in better survival, I do not know. 
As regards reconstruction, I think with the advent of 
synthetic prostheses, be they polytetrafluoroethylene or 
Marlex mesh, it has become so easy to place the material 
for reconstruction that perhaps we have extended our 
indications even for smaller skeletal defects. In this review 
we have some patients who had only 6 by 6 cm skeletal 
defects who underwent repair with Marlex mesh. It is true 
that in the smaller-sized defects cosmetics i probably the 
main reason for use of these prostheses, but in the larger 
defects it is more than cosmetic, it is reconciling and 
avoiding a flail chest. 
In the postoperative follow-up of these patients we do 
not have any specific recommendations. A  with all soft- 
tissne sarcomas and bone sarcomas, our main concern is 
local recurrence and pulmonary metastases, and follow-up 
with CT scanning to identify pulmonary metastases i
advisable. The frequency of this is individualized. Local 
recurrences are normally noted on routine visits of the 
patient to us. Ordinarily we see these patients every 3 
months for the first year or two and every 6 months 
thereafter. 
